Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma

Here we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotox...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Fatih M. Uckun
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Frontiers Media S.A. 2021-11-01
Serie:	Frontiers in Oncology
Ämnen:	tumor microenvironment (TME) multiple myeloma (MM) bispecific T-cell engagers (BiTEs) bispecific antibodies (BsABs) bone marrow microenvironment (BMME) myeloid-derived suppressor cells (MDSC)
Länkar:	https://www.frontiersin.org/articles/10.3389/fonc.2021.760382/full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!